
Because antibody-drug conjugates sit at the interface of antibody biology and small-molecule pharmacology, payload-led design brings those disciplines together, earlier.
Allan Jordan, PhD, is Vice President of Oncology Drug Discovery at Sygnature Discovery. He has extensive experience developing targeted therapeutics and advancing integrated drug discovery programs. Drawing on a background in medicinal chemistry, he focuses on optimizing payload properties and designing antibody-drug conjugates to improve clinical tolerability, ensuring that novel therapeutics can successfully navigate the complexities of late-stage development.